Trial Profile

A Randomized Phase 3 Study of MRTX849 in Combination With Cetuximab Versus Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation With Disease Progression On or After Standard First-Line Therapy

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 14 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Adagrasib (Primary) ; Cetuximab (Primary) ; Aflibercept; Bevacizumab; Fluorouracil; Folinic acid; Irinotecan; Oxaliplatin; Ramucirumab
Indications Carcinoma; Colorectal cancer
Focus Registrational; Therapeutic Use
Acronyms KRYSTAL-10; KRYSTAL10
Sponsors Mirati Therapeutics

09 Jan 2025 Planned End Date changed from 28 Feb 2026 to 30 Jan 2026.
09 Jan 2025 Planned primary completion date changed from 28 Feb 2025 to 30 Jan 2026.
12 Mar 2024 Planned End Date changed from 30 Dec 2024 to 28 Feb 2026.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com